The Quotes are Powered By Forexpros, the Forex, Futures, and Stock Markets Portal.

News Headlines and Feed

Business News Videos

Meda acquires Women’s Health products in the U.S

Thursday, 06 September 2012
Meda has signed an agreement with the U.S. company, Jazz Pharmaceuticals to acquire a portfolio of 6 pharmaceutical products focused on Women’s Health.

The largest and most important product is Elestrin, a patented product with sales of almost 100 MSEK. Elestrin is indicated for the treatment of moderate-to-severe vasomotor symptoms (i.e. hot flashes) associated with menopause. Since the launch in 2007, Elestrin has become a leading brand in the topical ERT (estrogen replacement therapy) market. Together with Meda’s present portfolio of products in the therapy area of Women`s Health the sales will be over 500 MSEK.

“We can now strengthen the product offering in the U.S. as well as expand our sales force with people that have good experience and excellent track-record", said Anders Lönner, CEO of Meda AB. "Meda has already a presence in the Women’s Health area and this deal will create positive marketing synergies”.
The closing of the acquisition is subject to the satisfaction of customary closing conditions and regulatory approvals, including antitrust approvals. With an anticipated closing of the acquisition during the 4th quarter this year, the effect on Meda’s earnings per share is expected to be accretive already during 2013. Meda’s existing credit facilities will finance the acquisition.
Based on a press release